Intervention to reduce carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit

Infect Control Hosp Epidemiol. 2020 Jun;41(6):710-715. doi: 10.1017/ice.2020.35.

Abstract

Objective: To investigate the effects of environmental cleaning and the installation of heat and moisture exchangers (HMEs) to reduce neonatal carbapenem-resistant Acinetobacter baumannii (CRAB) sepsis and colonization as well as antimicrobial use.

Design: We conducted a 7-year, quasi-experimental study.

Setting and patients: All neonates admitted to a neonatal intensive care unit (NICU).

Methods: We compared the trends for CRAB sepsis and colonization before (period 1, 2011-2013) and after (period 3, 2015-2017) a 12-month intervention period in 2014 (period 2) to incorporate a combination of HME use and sodium hypochlorite cleaning (5,000 ppm in the NICU and 500 ppm in the neonatal environment) using interrupted time series analysis with segmented regression.

Results: During the 7-year study period, 3,367 neonates were admitted to the NICU; the prevalence rates of CRAB sepsis and endotracheal CRAB colonization were 0.5 per 1,000 patient days, and 19.4 per 1,000 ventilator days. A comparison of period 1 to period 3 showed significant decreases in the percentages of both CRAB of A. baumannii sepsis (100% versus 11%) and endotracheal colonization (76% vs 52%) following the introduction of disposable HMEs and sodium hypochlorite cleaning (both P < .001). In period 3, compared with period 1, segmented regression analysis showed significant reductions in endotracheal CRAB colonization per 1,000 ventilator days (ie, change in level) and both carbapenem and colistin use (changes in both level and slope) (P < .001).

Conclusions: Interventions featuring environmental cleaning and use of HMEs led to a sustainable reduction of CRAB colonization coupled with a reduction in broad-spectrum antimicrobial use in the NICU.

MeSH terms

  • Acinetobacter Infections / drug therapy
  • Acinetobacter Infections / prevention & control*
  • Acinetobacter baumannii
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenems
  • Cross Infection / drug therapy
  • Cross Infection / prevention & control*
  • Humans
  • Infant, Newborn
  • Infection Control / methods*
  • Intensive Care Units, Neonatal*
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Carbapenems